| Identification | Back Directory | [Name]
FN-1501 | [CAS]
1429515-59-2 | [Synonyms]
1H-Pyrazole-3-carboxamide, N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- | [Molecular Formula]
C22H25N9O | [MDL Number]
MFCD31657383 | [MOL File]
1429515-59-2.mol | [Molecular Weight]
431.49 |
| Chemical Properties | Back Directory | [density ]
1.427±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 50 mg/mL (115.88 mM) | [form ]
Solid | [pka]
11.73±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity. | [in vivo]
FN-1501 exhibits potent antitumor activity, and shows little cytotoxicity on normal lymphocyte cells, with LD50 of 185.67 mg/kg in ICR mice. FN-1501 (15. 30, or 40 mg/kg/d, i.v.) dose-dependently and significantly suppresses the growth of tumor in MV4-11-cell-inoculated-xenograft mice[1]. | [IC 50]
Cdk4/cyclin D1: 0.85 nM (IC50); CDK6/cyclinD1: 1.96 nM (IC50); cdk2/cyclin A: 2.47 nM (IC50); FLT3: 0.28 nM (IC50) | [References]
[1] Wang Y, et al. Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. DOI:10.1021/acs.jmedchem.7b01261 |
|
|